PASITHEA THERAPEUTICS CORP. Cost, Amortization
PASITHEA THERAPEUTICS CORP. (KTTA) reported Cost, Amortization of $315.08 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-11.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSoldAmortization · last filed 2023-08-11
- PASITHEA THERAPEUTICS CORP. cost, amortization for the quarter ending 2023-06-30 was $157.54K.
- PASITHEA THERAPEUTICS CORP. cost, amortization for the quarter ending 2023-03-31 was $157.54K.
- PASITHEA THERAPEUTICS CORP. cost, amortization for fiscal 2022 was $854.00.
| Period end | Cost, Amortization 3 month | Cost, Amortization 6 month | Cost, Amortization 12 month |
|---|---|---|---|
| 2023-06-30 | $157.54K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $315.08K 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $157.54K 10-Q · filed 2023-05-12 | ||
| 2022-12-31 | $854.00 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Rocket One Inc. (RKTO) | United States | $0.019B |